Total body BMD measured by DEXA (% change from baseline) · people with sickle cell disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events · people with sickle cell disease
Vitamin D showed no clear difference in adverse events compared with placebo (low certainty).
1 finding from 1 review
Pain frequency or change in pain frequency · people with sickle cell disease
1 finding from 1 review
Acute chest syndrome ( · people with sickle cell disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Respiratory infections · people with sickle cell disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
HRQoL score (physical functioning) (change from baseline) · people with sickle cell disease
1 finding from 1 review
Linear growth (length/height) Unit: cm Time frame: 3 months · children under 5 years of age
1 finding from 1 review
Mean height‐for‐age z‐score · children under 5 years of age
1 finding from 1 review
Stunting · children under 5 years of age
Vitamin D showed no clear difference in stunting Definition: L/HAZ < ‐2Time frame: 6 months compared with placebo or no intervention (moderate certainty).
1 finding from 1 review
Adverse effect: hypercalciuria As defined by trialists Time frame: 3 months · children under 5 years of age
Vitamin D showed no clear difference in adverse effect: hypercalciuria As defined by trialistsTime frame:… compared with placebo or no intervention (moderate certainty).
1 finding from 1 review
Hypercalcaemia · children under 5 years of age
It is very uncertain whether vitamin D changes adverse effect: hypercalcaemia As defined by trialistsTime frame:… compared with placebo or no intervention (very low certainty).
1 finding from 1 review
Adverse effect: hyperphosphataemiae · children under 5 years of age
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse effect: kidney stonesb · children under 5 years of age
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Tardive dyskinesia: No clinically important improvement · patients with antipsychotic‐induced tardive dyskinesia
VITAMIN E showed no clear difference in tardive dyskinesia: 1. Not improved to a clinically important extent compared with PLACEBO (low certainty).
1 finding from 1 review
Tardive dyskinesia: Deterioration of symptoms · patients with antipsychotic‐induced tardive dyskinesia
VITAMIN E may leads to lower tardive dyskinesia: 3. Deterioration of symptoms compared with PLACEBO (low certainty).
1 finding from 1 review
Adverse effect: any · patients with antipsychotic‐induced tardive dyskinesia
It is very uncertain whether VITAMIN E changes adverse effect: any compared with PLACEBO (very low certainty).
1 finding from 1 review
Adverse effects/events ‐ extrapyramidal symptoms ‐ medium term Number of instances of extrapyramidal symptoms · patients with antipsychotic‐induced tardive dyskinesia
1 finding from 1 review
Leaving the study early · patients with antipsychotic‐induced tardive dyskinesia
It is very uncertain whether VITAMIN E changes acceptability of treatment (measured by participants leaving the… compared with PLACEBO (very low certainty).
1 finding from 1 review
Social confidence, social inclusion, social networks, or personalised quality of life · patients with antipsychotic‐induced tardive dyskinesia
1 finding from 1 review
Cognitive subdomain: episodic memory measured at the end of · MCI
1 finding from 1 review
no estimate extracted
1 study · 1 participants
Low